Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

Paused · Not applicable

Conditions studied: Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH), Non-Langerhans-Cell Histiocytosis

In brief

The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the understanding of the chemistry of these disorders and identify potential actionable mutations that can be targeted with therapies in the context of clinical trials.

Key facts

Study ID

NCT05028621

Run by

Case Comprehensive Cancer Center

People needed

135

Starts

2021-06-18

Expected to finish

2026-09-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have histopathologic confirmation of the particular rare hematologic disease.
• Diseases that will be considered as rare hematologic diseases for this study will include the following
• Langerhans cell histiocytosis (LCH)
• Erdhiem Chester disease (ECD)
• Rosai-Dorfman disease (RDD)
• Miscellaneous histiocytic entities -indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, fibroblastic reticular cell tumor
• Unicentric Castleman disease
• Multicentric Castleman disease including TAFRO
• Follicular Dendritic Cell sarcoma (FDCS)
• Newly diagnosed treatment naïve patients as well as patients who received prior therapies (e.g. chemotherapy, targeted therapy, surgery, or radiation) will be included. -Tissue specimens collected within the past 5 yearse will be considered acceptable for study inclusion will include the following
• Collected as part of the evaluation for diagnostic confirmation
• Tissue specimen or extracted DNA (from blood sample) banked in IRB approved tissue repositories and obtained within five years prior to the date of informed consent. -Tissue samples are planned to be collectedfrom previously stored surgical specimens already being stored in pathology lab
• Consent to have germline testing performed in parallel to tumor testingg)Patients willing to receive treatmen

You may not qualify if…

• Life expectancy of less than 6months
• Patient unwilling to have germline testing performed on peripheral blood or buccal mucosa

Where it is running

• Cleveland Clinic, Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.